Health AI Central
Share:
Peer-Reviewed Publication
Proc Natl Acad Sci U S A2025;122(39):e2522286122.September 30, 2025Letter

Software-Enhanced Drugs™: The third platform reshaping drug development.

Shaheen E Lakhan1, Paul Wicks2
1Click Therapeutics, Inc., New York, NY 10013.
2Wicks Digital Health Ltd., Lichfield WS13 6DN, United Kingdom.
PubMed PMC DOI PDF

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.